Enhancing Nasopharyngeal Cancer Follow-up: 68 Ga-Trivehexin PET/CT for Distinguishing Recurrence From Infection.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 40590065.
- Also identified by DOI 10.1097/RLU.0000000000006015.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The role of 18 F-FDG PET/CT (FDG) in detecting recurrence of nasopharyngeal squamous cell carcinoma (NFSCC) is undeniably high; however, hypermetabolism due to infection/inflammation can lead to false-positive interpretation. 68 Ga-Trivehexin PET/CT (TRV-PET), a new PET imaging agent used to visualize αVβ6 integrin receptors, has shown promising results in overcoming false-positive FDG uptake in lymph node metastases in head and neck tumors. This case report compares the findings of 68 Ga-Trivehexin PET/CT with 18 F-FDG PET/CT, 99m Tc-MDP bone scintigraphy (BS), and 99m Tc-HMPAO labeled leukocyte scintigraphy (LLS) in the differential diagnosis of local recurrence/infection in a patient with a history of NFSCC.
Medical subject headings
- Positron Emission Tomography Computed Tomography
- Nasopharyngeal Neoplasms
- Gallium Radioisotopes
- Infections
- Neoplasm Recurrence, Local